Clinico-biological characteristics and outcome of hepatitis C virus-positive patients with diffuse large B-cell lymphoma treated with immunochemotherapy
详细信息 查看全文
- 作者：Ivan Dlouhy ; Miguel Á. Torrente ; Sabela Lens ; Jordina Rovira…
- 关键词：Diffuse large B cell lymphoma ; Hepatitis C virus ; Immunochemotherapy ; Hepatic toxicity ; Outcome
- 刊名：Annals of Hematology
- 出版年：2017
- 出版时间：March 2017
- 年：2017
- 卷：96
- 期：3
- 页码：405-410
- 全文大小：
- 刊物类别：Medicine
- 刊物主题：Hematology; Oncology;
- 出版者：Springer Berlin Heidelberg
- ISSN：1432-0584
- 卷排序：96
文摘
Diffuse large B cell lymphoma (DLBCL) patients carrying hepatitis C virus (HCV) have higher risk of treatment toxicity and complications. The aim of this study was to assess the impact of HCV in a series of DLBCL patients treated with immunochemotherapy. 321 patients (161 M/160F; median age, 66 years) diagnosed with de novo DLBCL in a single center between 2002 and 2013 were included. Immunodeficiency-related lymphomas were excluded. HCV+ cases were defined by the presence of IgG anti-HCV. Main clinico-biological characteristics and outcome were analyzed according to the viral status. Two hundred ninety patients were HCV− and 31 HCV+. HCV+ patients were older (median age 71 vs. 64 years, P = 0.03), had more often B symptoms (P = 0.013), spleen (P = 0.003), and liver (P = 0.011) involvement, higher rate of early death (<4 months, P = .001), and shorter overall survival (OS). Eleven HCV+ patients had cirrhosis criteria. HCV+ patients with impaired liver function before or during treatment showed inferior OS. Elevated pre-treatment bilirubin correlated also with higher liver toxicity. In a multivariate analysis that included R-IPI score, serum beta2-microglobulin (β2m), HCV status, and presence of cirrhosis, only R-IPI, β2m, and cirrhosis showed independent prognostic impact on OS. The presence of HCV in DLBCL patients entails higher number of complications and early deaths; however, liver impairment and not the hepatitis viral status was the key feature in the outcome of the patients.